REVISITING HYPERBARIC OXYGEN THERAPY IN ACUTE MYOCARDIAL INFARCTION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF CARDIAC RECOVERY AND SURVIVAL OUTCOMES

Clicks: 8
ID: 330986
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #324 of 330 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 330 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background and Aims Hyperbaric oxygen therapy (HBOT) has been proposed as an adjunctive treatment in acute myocardial infarction (AMI) due to its potential to enhance oxygen delivery and attenuate ischemia–reperfusion injury. However, its clinical benefit in the era of modern reperfusion therapy remains uncertain. Methods A systematic search was conducted in four databases to identify studies involving adult patients with AMI treated with HBOT compared with standard therapy up to March 2026. Outcomes of interest included mortality, creatine phosphokinase (CPK) levels, and left ventricular ejection fraction (LVEF). Pooled estimates were calculated using a random-effects model. Data regarding HBOT protocols, timing of administration relative to reperfusion, and reported adverse events, were also extracted for qualitative analysis. Results Nine studies involving a total of 1,401 participants (HBOT: n = 681; control: n = 720) were included. HBOT was associated with a significant reduction in mortality (RR = 0.43; 95% CI 0.24–0.79; p = 0.006), with greater benefit observed in long-term follow-up (RR = 0.28; 95% CI 0.16–0.51; p < 0.001), while no significant reduction was found in short-term mortality. HBOT also significantly reduced CPK levels (SMD = −0.42; 95% CI −0.66 to −0.17; p < 0.001) and improved LVEF (MD = 3.69%; 95% CI 1.24–6.14; p = 0.003). Heterogeneity across analyses was low to moderate. Conclusion HBOT as an adjunctive therapy in AMI is associated with improved clinical outcomes, particularly in long-term mortality and myocardial recovery.Figure 1.Graphical representation of hyperbaric oxygen therapy (HBOT) in acute myocardial infarction
Reference Key
openalex_W7220375316 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors K T Zenjaya, Leoni, L Handoko, R N Rosyadi
Are you one of these authors? Claim your profile
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag119.032
URL
https://doi.org/10.1093/eurheartjsupp/suag119.032
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.